17 November 2015: Quality & Compliance with GRS - free 1-1 sessions at the Life Sciences Hub, Cardiff

Tuesday 17th November is your opportunity to ‘drop-in’ at the Life Sciences Hub in Cardiff and visit Bobby and Greer Deal, Directors of GRS, to gain clarity on the regulations which may apply to your product. There really is no such thing as a ‘silly question’: if you’re thinking it, you can be 100% certain that others will be thinking it too! Please come and ask us: we’re here to help, to cut through the regulatory and quality compliance maze and to provide some light on what, at times, can feel like a somewhat murky subject.

Global Regulatory Services is voted "Best for Life Science Regulatory Compliance Solutions, 2015"

17 August 2015: Corporate Vision magazine names Global Regulatory Services (GRS) as one of the winners of the 2015 Global Product & Services Awards.

Global Regulatory Services (GRS) Launches New Support Ecosystem for Biologics Sector

14 July 2015 – Cambridge, UK.  Global Regulatory Services (GRS) launches a truly holistic service for the Biologics Sector providing a pathway from concept to the patient. 

Borderline medical products: a crisis of identity or an opportunity to build the brand?

Global Regulatory Services (GRS) is delighted to announce that an article written by Greer Deal, Director, has been published in the July/August edition of the Regulatory Rapporteur (the journal produced by The Organisation for Professionals in Regulatory Affairs - TOPRA). This article highlights the importance of confirming (and agreeing on) a product's identity especially when one product can have two or even three different identities!

GRS Features at Glittering Awards Evening at Royal College of Surgeons, London

9 December 2014: The TOPRA Awards for Regulatory Excellence is an annual event to say a big ‘thank you’ to regulatory professionals, our unsung heroes of the Life Sciences.  This year two new categories were added and Greer Deal, Director of Global Regulatory Services (GRS), was one of the three individuals shortlisted for one of these new categories, “Futures”.  This particular category acknowl

Is Medical Device and IVD regulation moving in the Pharma direction?

Join in the debate at the One Nucleus Genesis Conference on Tuesday 9th December 2014 at the QEII Conference Centre, Westminster, London.

Greer Deal, Director of Global Regulatory Services, is chairing this session at 11:30 with Neil Adams of the BSI providing fuel for discussion by presenting an update on the new draft European Medical Device & IVD Regulations.

Shortlisted for TOPRA Awards for Regulatory Excellence - Futures Category

Greer Deal, Director of Global Regulatory Services (GRS), is delighted to be shortlisted for the TOPRA Futures Award especially because the Award is so relevant to GRS and the company strap line "driving innovation to market success".

Press Release: “Babylon app puts a GP in your pocket” - Global Regulatory Services provides guidance

19 May 2014 – Cambridge, UK.  Global Regulatory Services (GRS) is delighted with the response their client, Babylon Partners, has received to the launch of the babylon health app.  They launched the app to an audience of 5,000 at the Royal Albert Hall and were “humbled by the response”:

The Telegraph:"Set to revolutionise the healthcare system and eradicate waiting lists for subscribers."
Daily Express:“Ground-breaking…Babylon phone app puts a doctor in your pocket."
The Times:

"Blame the breast implants": GRS is featured in Cambridge Business Magazine

Global Regulatory Services (GRS) is featured in the May 2014 edition of the Cambridge Business Magazine.  The article is entitled "Blame the breast implants" - eye catching to say the least!

SME Status means GRS clients can get 90-100% discount on EMA fees

Global Regulatory Services (GRS) is delighted to announce that on 25 April 2014 the company was awarded EU SME Status.  So what does this actually mean?  It means that our clients can take advantage of many incentives provided by Europe for SMEs developing innovative and new medicines for both human and veterinary patients.  Crucially, there are a couple of very attractive fee discounts on offer: